YIBAI PHARMACEUTICAL(SH:600594) Sou Hu Cai Jing·2026-01-21 23:12Group 1 - Riel Group's shares have been suspended from trading since December 1, 2025, due to concerns raised by auditors regarding related payments, leading to the establishment of an independent investigation committee [1] - The company has delayed the publication of its 2025 interim results and report, highlighting the importance of compliance and governance in listed companies [1] - The investigation's outcome remains uncertain, raising market concerns and emphasizing the need for strict adherence to governance standards in the industry [1] Group 2 - Aotai Biotech plans to repurchase its shares using 100 million to 200 million RMB of funds raised from its initial public offering, with a buyback price not exceeding 85 RMB per share [2] - This move reflects the company's confidence in its value and aims to enhance shareholder returns by reducing registered capital through share cancellation [2] - The buyback initiative is seen as a positive response to market conditions and aims to boost investor confidence [2] Group 3 - Yibai Pharmaceutical expects a net loss attributable to shareholders of 285 million to 342 million RMB for 2025, with a projected revenue decline of 14% due to decreased sales of its main products [3] - Despite a forecasted 18% reduction in costs, expenses are still expected to exceed revenue, leading to continued losses [3] - The company plans to recognize goodwill impairment of 110 million to 132 million RMB, further exacerbating its financial challenges [3] Group 4 - Heng Rui Medicine has received approval for clinical trials of two drugs, SHR-7787 and Abedilizumab, from the National Medical Products Administration [4] - The approval underscores the company's strength in innovative drug development and enhances its product pipeline in the oncology sector [4] - The advancement of these clinical trials is expected to solidify Heng Rui's position in the industry and contribute to the growth of cancer treatment options [4]